Higher dose tested for lung cancer patients not responding enough to standard treatment
NCT ID NCT07298148
Summary
This study is testing whether increasing the dose of the drug firmonertinib can help patients with advanced lung cancer who have a specific genetic mutation. The trial is for people whose cancer has only stayed stable, not shrunk, after 8 weeks on the standard lower dose. Researchers want to see if the higher dose can better control the cancer and is safe for patients to take daily.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC STAGE IV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.